One analyst called this a "best-case" scenario for the company's experimental depression treatment.
A biotech company's experimental LSD-based drug for depression has shown promising results. An analyst lauded the outcome as a "best-case scenario" for the treatment. This positive development has propelled the company's stock significantly higher, indicating strong investor…
Market Samachar is a news aggregator. This article was originally published by Investor's Business Daily. Tap the button above to read the full story on their site.